Literature DB >> 17915077

The future of vaccines in the management of addictive disorders.

Frank M Orson1, Berma M Kinsey, Rana A K Singh, Yan Wu, Tracie Gardner, Thomas R Kosten.   

Abstract

Conventional substance abuse treatments have had only limited success. As a result, new approaches, including vaccination to block the effects of drugs such as cocaine, nicotine, methamphetamine, and phencyclidine, are in development. Although a number of possible rationales for the effects of antidrug vaccines have been suggested, the most straightforward and intuitive mechanism would involve binding of the drug by antibodies in the bloodstream, thereby blocking entry or reducing the rate of entry of the drug into the central nervous system. The theoretical parameters that would influence vaccine-induced drug pharmacodynamics are presented in this review, along with the current status on vaccine development for nicotine, cocaine, methamphetamine, and phencyclidine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17915077     DOI: 10.1007/s11920-007-0049-z

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  40 in total

Review 1.  Development of vaccines to help treat drug dependence.

Authors:  Campbell J Bunce; Peter T Loudon; Catherine Akers; Jennifer Dobson; Doreen M Wood
Journal:  Curr Opin Mol Ther       Date:  2003-02

2.  VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE.

Authors:  H N EISEN; G W SISKIND
Journal:  Biochemistry       Date:  1964-07       Impact factor: 3.162

3.  Human therapeutic cocaine vaccine: safety and immunogenicity.

Authors:  Thomas R Kosten; Marc Rosen; Julian Bond; Michael Settles; John St Clair Roberts; John Shields; Lindsay Jack; Barbara Fox
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

4.  Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats.

Authors:  J W Proksch; W B Gentry; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

5.  Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.

Authors:  W Brooks Gentry; Elizabeth M Laurenzana; D Keith Williams; Jeremy R West; Renata J Berg; Teodora Terlea; S Michael Owens
Journal:  Int Immunopharmacol       Date:  2006-02-09       Impact factor: 4.932

6.  Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls.

Authors:  Jennifer M Mitchell; Venessa C Tavares; Howard L Fields; Mark D'Esposito; Charlotte A Boettiger
Journal:  Neuropsychopharmacology       Date:  2006-10-18       Impact factor: 7.853

7.  Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.

Authors:  J L Valentine; M Mayersohn; W D Wessinger; L W Arnold; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

8.  Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.

Authors:  J L Valentine; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

Review 9.  Therapeutic vaccines for substance dependence.

Authors:  Margaret Haney; Thomas R Kosten
Journal:  Expert Rev Vaccines       Date:  2004-02       Impact factor: 5.217

10.  Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat.

Authors:  D E McMillan; W C Hardwick; M Li; M G Gunnell; F I Carroll; P Abraham; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  2004-03-01       Impact factor: 4.030

View more
  16 in total

Review 1.  Pharmacokinetic strategies for treatment of drug overdose and addiction.

Authors:  David A Gorelick
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  [Immunotherapies for drug addictions].

Authors:  Ivan Montoya
Journal:  Adicciones       Date:  2008       Impact factor: 2.979

3.  Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine.

Authors:  Frank M Orson; Roger D Rossen; Xiaoyun Shen; Angel Y Lopez; Yan Wu; Thomas R Kosten
Journal:  Am J Addict       Date:  2013-02-01

Review 4.  Adjuvants for vaccines to drugs of abuse and addiction.

Authors:  Carl R Alving; Gary R Matyas; Oscar Torres; Rashmi Jalah; Zoltan Beck
Journal:  Vaccine       Date:  2014-08-08       Impact factor: 3.641

5.  Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial.

Authors:  Thomas R Kosten; Coreen B Domingo; Daryl Shorter; Frank Orson; Charles Green; Eugene Somoza; Rachelle Sekerka; Frances R Levin; John J Mariani; Maxine Stitzer; D Andrew Tompkins; John Rotrosen; Vatsal Thakkar; Benjamin Smoak; Kyle Kampman
Journal:  Drug Alcohol Depend       Date:  2014-04-16       Impact factor: 4.492

Review 6.  New directions in nicotine vaccine design and use.

Authors:  Paul R Pentel; Mark G LeSage
Journal:  Adv Pharmacol       Date:  2014

Review 7.  Vaccines for cocaine abuse.

Authors:  Frank M Orson; Berma M Kinsey; Rana A K Singh; Yan Wu; Thomas R Kosten
Journal:  Hum Vaccin       Date:  2009-04-20

Review 8.  Can you vaccinate against substance abuse?

Authors:  Thomas R Kosten; Coreen B Domingo
Journal:  Expert Opin Biol Ther       Date:  2013-04-18       Impact factor: 4.388

Review 9.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

10.  Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans.

Authors:  Margaret Haney; Erik W Gunderson; Huiping Jiang; Eric D Collins; Richard W Foltin
Journal:  Biol Psychiatry       Date:  2010-01-01       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.